产品说明书
SLC13A5-IN-1
 |
同义名 : | - |
| CAS号 : | 2227548-95-8 | |
| 货号 : | A1250015 | |
| 分子式 : | C19H19Cl3N2O3S | |
| 纯度 : | 99%+ | |
| 分子量 : | 461.79 | |
| MDL号 : | - | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 12 mg/mL(25.99 mM)，配合低频超声，并水浴加热至45℃助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | SLC13A5-IN-1 is a specific inhibitor of the sodium-citrate co-transporter (SLC13A5). It completely inhibits the uptake of 14C-citrate in HepG2 cells, with an IC50 value of 0.022 μM. SLC13A5-IN-1 shows promise for the treatment of metabolic and/or cardiovascular diseases. This compound is derived from patent WO2018104220A1, specifically Compound I-5[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.17mL 0.43mL 0.22mL |
10.83mL 2.17mL 1.08mL |
21.65mL 4.33mL 2.17mL |
| 参考文献 |
|---|